Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Elisa Giovannetti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7565-7504; OpenAlex author ID A5041229832. Sources: OpenAlex.

Their work

Papers
147 (first author 7, last author 56)
Trials
0
Grants
0
Labs led
2
Collaborators
242
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: 3 papers · 2014: 9 papers · 2015: 6 papers · 2016: 3 papers · 2017: 7 papers · 2018: 4 papers · 2019: 11 papers · 2020: 11 papers · 2021: 11 papers · 2022: 16 papers · 2023: 12 papers · 2024: 24 papers · 2025: 11 papers · 2026: 12 papers

Papers 50 of 147

  1. CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer. Last author DOI 10.1016/j.canlet.2026.218851↗
  2. Eph receptors in pancreatic cancer: Biological roles and clinical implications. Last author DOI 10.1016/j.critrevonc.2026.105299↗
  3. AISP position statement: Standardising biological sample collection and handling for advanced diagnostics and multi-omic analyses in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.08.021↗
  4. The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance. Last author DOI 10.1016/j.drup.2026.101408↗
  5. Protocol for eVLP-mediated CRISPR-Cas9 and prime editing in pancreatic cancer cell lines. Co-author DOI 10.1016/j.xpro.2026.104904↗
  6. Proteomics of Extracellular Vesicles Derived from Primary Cells of Pancreatic Ductal Adenocarcinoma Patients Identifies Ribosomal Proteins Associated with Surv… Co-author DOI 10.1021/acs.jproteome.6c00168↗
  7. Molecular subtypes in pancreatic cancer: from academic promise to clinical reality. Co-author DOI 10.1186/s12943-026-02614-9↗
  8. Fluid shear stress enhances pancreatic cancer motility through YAP activation. Last author DOI 10.1186/s13148-026-02163-4↗
  9. Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them. Last author DOI 10.20517/cdr.2026.52↗
  10. Longitudinal Circulating Nerve Growth Factor in Pancreatic Ductal Adenocarcinoma: An Exploratory Study of Postoperative Recurrence and First-Line Disease Contr… Last author DOI 10.3390/biom16101433↗
  11. Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/life16091499↗
  12. Coordinated immune architecture underlies durable survival in pancreatic cancer Co-author DOI 10.64898/2026.04.29.721612↗
  13. Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models. Co-author DOI 10.1002/cmdc.202500448↗
  14. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions. Co-author DOI 10.1002/ueg2.70118↗
  15. Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic c… Co-author DOI 10.1016/j.bioorg.2024.107995↗
  16. The potential application of stroma modulation in targeting tumor cells: Focus on pancreatic cancer and breast cancer models. Co-author DOI 10.1016/j.semcancer.2025.05.003↗
  17. Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors. Co-author DOI 10.1016/j.semcancer.2025.06.001↗
  18. Navigating the paradox of senescence and chemoresistance in pancreatic cancer. Last author DOI 10.1016/j.semcancer.2025.06.007↗
  19. Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts. Co-author DOI 10.1038/s41598-025-24863-2↗
  20. 18F-Prostate-Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN-2): a phase I/II study. Co-author DOI 10.1186/s40644-025-00822-y↗
  21. Peripheral blood neutrophil-to-lymphocyte ratio as a prognostic marker and its association with the tumor-immune microenvironment in pancreatic cancer: a retro… Co-author DOI 10.21037/jgo-2025-283↗
  22. Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/biom15071018↗
  23. New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/md23080327↗
  24. Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues. Co-author DOI 10.1002/1878-0261.13625↗
  25. Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-024-04712-1↗
  26. Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic cancer models. Co-author DOI 10.1016/j.bioorg.2024.107959↗
  27. Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cells. Last author DOI 10.1016/j.ijrobp.2023.10.035↗
  28. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  29. Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems. Last author DOI 10.1016/j.semcancer.2024.09.002↗
  30. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions. Co-author DOI 10.1038/s42003-024-06087-8↗
  31. Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, … Co-author DOI 10.1080/1061186x.2024.2385557↗
  32. The trend toward more target therapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1080/14737140.2024.2357802↗
  33. Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer. Last author DOI 10.1080/15257770.2024.2319215↗
  34. Metabolites derived from gut microbiota mitigate chemoresistance in pancreatic cancer. Last author DOI 10.1080/17474124.2024.2412045↗
  35. Implications of the microbiome after pancreatic cancer resection with regard to morbidity and mortality. Co-author DOI 10.1080/17474124.2024.2427648↗
  36. Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study. Co-author DOI 10.1093/bjsopen/zrad119↗
  37. The microbial composition of pancreatic ductal adenocarcinoma: a systematic review of 16S rRNA gene sequencing. Co-author DOI 10.1097/js9.0000000000001762↗
  38. In-depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations. Co-author DOI 10.1111/cas.16147↗
  39. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells. Co-author DOI 10.1186/s13046-023-02879-8↗
  40. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
  41. Targeting ABC transporters in PDAC - past, present, or future? First author DOI 10.18632/oncotarget.28597↗
  42. NGF-mediated crosstalk: unraveling the influence of metabolic deregulation on the interplay between neural and pancreatic cancer cells and its impact on patien… Co-author DOI 10.3389/fphar.2024.1499414↗
  43. Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. Co-author DOI 10.3390/cancers16223863↗
  44. Targeting Perineural Invasion in Pancreatic Cancer. First author DOI 10.3390/cancers16244260↗
  45. Unraveling the Connection: Pancreatic Cancer Cells and Schwann Cells. Last author DOI 10.3390/jcm13061785↗
  46. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.4155/fmc-2023-0234↗
  47. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. Last author DOI 10.7150/ijbs.92671↗
  48. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  49. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10555-023-10127-w↗
  50. Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2023.112581↗

Closest collaborators

The 25 strongest of 242 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geert Kazemier M · 32 shared papers, 2013–2026 · strength 4.25
  2. Ingrid Garajová · 22 shared papers, 2014–2026 · strength 4.00
  3. Adam Enver Frampton · 32 shared papers, 2013–2026 · strength 3.86
  4. Godefridus J. Peters · 36 shared papers, 2011–2026 · strength 3.79
  5. Luca Morelli · 18 shared papers, 2021–2026 · strength 3.64
  6. Annalisa Comandatore · 15 shared papers, 2021–2026 · strength 3.06
  7. Patrizia Diana · 18 shared papers, 2019–2025 · strength 2.97
  8. Daniela Carbone · 17 shared papers, 2019–2025 · strength 2.83
  9. Tessa Y. S. Le Large · 23 shared papers, 2014–2026 · strength 2.76
  10. Barbara Parrino · 15 shared papers, 2019–2025 · strength 2.46
  11. Stella Cascioferro · 15 shared papers, 2019–2025 · strength 2.35
  12. Camilla Pecoraro · 12 shared papers, 2021–2025 · strength 2.25
  13. Geng Xu · 9 shared papers, 2022–2025 · strength 2.04
  14. Niccola Funel · 32 shared papers, 2011–2022 · strength 2.04
  15. Mjriam Capula · 12 shared papers, 2019–2024 · strength 1.86
  16. Laura L. Meijer · 15 shared papers, 2015–2024 · strength 1.68
  17. Dongmei Deng · 9 shared papers, 2018–2026 · strength 1.67
  18. Alessandro Gregori · 10 shared papers, 2020–2024 · strength 1.64
  19. Mahrou Vahabi · 6 shared papers, 2023–2026 · strength 1.50
  20. Lenka N.C. Boyd · 9 shared papers, 2020–2024 · strength 1.46
  21. Jisce R. Puik · 8 shared papers, 2021–2025 · strength 1.43
  22. Cecilia Bergonzini · 7 shared papers, 2020–2024 · strength 1.42
  23. Giulia Lencioni · 5 shared papers, 2024–2026 · strength 1.40
  24. Juan Deng · 5 shared papers, 2024–2026 · strength 1.34
  25. Hanneke W.M. van Laarhoven · 10 shared papers, 2017–2024 · strength 1.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.